Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Agache, Ioana; Beltran, Jessica; Akdis, Cezmi; Akdis, Mubeccel; Canelo‐Aybar, Carlos; Walter Canonica, Giorgio; Casale, Thomas; Chivato, Tomas; Corren, Jonathan; Del Giacco, Stefano; Eiwegger, Thomas; Firinu, Davide; E. Gern, James; Hamelmann, Eckard; Hanania, Nicola; Mäkelä, Mika; Hernández‐Martín, Irene; Nair, Parameswaran; O'Mahony, Liam; G. Papadopoulos, Nikolaos; Papi, Alberto; Park, Hae‐Sim; Pérez de Llano, Luis; Posso, Margarita; Rocha, Claudio; Quirce, Santiago; Sastre, Joaquin; Shamji, Mohamed; Song, Yang; Steiner, Corinna; Schwarze, Jurgen; Alonso‐Coello, Pablo; Palomares, Oscar; Jutel, Marek

doi:10.1111/all.14221

Public

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Shared by NobleBlocks on Feb 24, 2020 • 12:00 AM UTC

Authors:

Ioana Agache

Jessica Beltran

Cezmi Akdis

Abstract

Abstract Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinoph...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!